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The normal tissue tolerance levels to fractionated radiotherapy have been appreciated by a century of careful clinical
observations and radiobiological studies in animals. During clinical fractionated radiotherapy, these normal tissue tolerance
levels are respected, and severe sequelae of radiotherapy are avoided in the majority of patients. Notwithstanding, a minority
of patients experience unexpectedly severe normal tissue reactions. The ability to predict which patients might form this
minority would be important. We have conducted a study to develop a rapid and reliable diagnostic test to predict excessive
normal tissue toxicity (NTT) in radiotherapy patients. A flow cytometric immunocytochemical assay was used to measure DNA
damage in peripheral blood lymphocytes (PBL) from cancer patients exposed to 2-Gy gamma radiation. DNA damage and
repair was measured by induction of cellular c-H2AX in unirradiated and exposed cells at specific time points following
exposure. In 12 cancer patients that experienced severe atypical NTT following radiotherapy, there was a failure to repair DNA
double-strand breaks (DSB) as measured by c-H2AX induction and persistence. In ten cancer patients that experienced little or
no NTT and in seven normal (noncancer controls), efficient repair of DNA DSB was observed in the c-H2AX assay. We conclude
that a flow cytometric assay based on c-H2AX induction in PBL of radiotherapy patients may represent a robust, rapid and
reliable biomarker to predict NTT during radiotherapy. Further research is required with a larger patient cohort to validate this
important study.
Radiotherapy (RT) is an important form of treatment of both
local and regional disease with 50–60% of cancer patients
receiving radiotherapy at some stage, either as monotherapy
or in combination with surgery, chemotherapy and/or hor-
monal therapy.1 Improvements in tumour imaging, targeting
of radiotherapy and optimisation of delivery schedules have
led to significant improvements in tumour response and out-
comes, and reduction in normal tissue toxicity (NTT).2
Nonetheless, NTT remains a limiting factor in the treatment
of cancer.3
There is interpatient heterogeneity in acute and delayed
NTT during and after radiotherapy, a phenomenon that has
been observed for more than half a century.4 NTT has been
graded by the Radiation Therapy Oncology Group (RTOG)
into a standardised scale of acute and late responses for all
tissue types.3 High-dose radical RT prescriptions risk higher
levels of NTT, but it has long been appreciated that a small
minority of patients manifest an excessive reaction even to
low radiotherapy doses.5–7 Such ‘‘overreactors’’ (ORs) may
respond so extremely to radiotherapy that the side effects
are potentially lethal. Individuals with genetic defects in the
repair of ionising radiation-induced DNA double-stranded
breaks (DSB) are ORs, the classical example of such disease
being ataxia telangiectasia (A-T). Patients with A-T have
extreme clinical and cellular hypersensitivity to ionising
radiation, suffering neurodegeneration and increased cancer
incidence.8,9 These individuals are usually diagnosed early in
life because of the occurrence of recognisable clinical symp-
toms, and if requiring anticancer therapy will be treated in
such a way to minimise life-threatening toxicity. However,
asymptomatic and undiagnosed human DNA repair defects
may leave individuals with a predisposition to cancer and an
increased risk of overreacting during treatment. Such has
been the case with four paediatric patients at St. Bartho-
lomew’s Hospital, London (three with lymphoma and one
with angiosarcoma), which resulted in fatal clinical responses
to radiotherapy.10,11
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RT primarily exerts a cytotoxic effect by causing DNA
DSB in cells.12 The extent of normal cell damage and its
repair governs the degree of NTT experienced by the patient.
Most human cells have complex cellular DNA repair mecha-
nisms that can reverse the effects of DNA damage induced
by ionising radiation; these are physiological mechanisms to
increase cell survival and maintain genomic stability. There-
fore, the efficiency of DNA repair in cancer and normal cells
is likely to play an important role in both tumour response
and level of NTT experienced.
The desire to predict how individual patients respond to
RT has been a goal of clinical and experimental oncology for
many decades. A number of in vitro methods have been
examined for their potential in predicting ionising radiation
sensitivity. These include clonogenic cell survival assays,7 alka-
line comet assays13 and micronucleus assays.14 In addition,
attempts have been made to correlate the activity and expres-
sion of specific DNA repair genes and normal tissue response
using a variety of molecular methods.15 These methods have
been informative in defining genotoxic responses to radiation
and a variety of DNA-damaging agents, but have been of
limited use and potential as a rapid and technically simple test
to be applied in the clinical setting, particularly prospectively,
as they can take weeks or months to perform. Therefore, an
assay that can provide results within a short time period
before commencing RT is highly desirable.
To address this problem, we developed a flow cytometry
assay of c-H2AX as a predictive/clinical test to determine
patient radiosensitivity. An initial step in the cellular repair
of DNA DSB is the phosphorylation of the minor histone
H2AX protein to form the c-H2AX protein.16 Many thou-
sands of c-H2AX molecules accumulate at sites of DSB to
form discrete nuclear ‘‘foci’’, which can be visualised and
quantified by a number of methods including in situ immu-
nocytochemistry or flow cytometry. The number of foci is in-
dicative of DNA DSB.17 Normally, with the passage of time
(and over a predictable time in the presence of normal physi-
ological repair mechanisms), the level of c-H2AX diminishes
as repair is completed; persistence of c-H2AX indicates
impaired DNA repair.
Our study aimed to examine whether there were signifi-
cant differences in c-H2AX depletion in irradiated peripheral
blood lymphocytes (PBL) between patients who had devel-
oped excessive NTT from radiotherapy and control groups.
Material and Methods
Subject selection
Three groups of subjects were recruited to our study, which
had been approved by local NHS ethics committee. Twelve
patients who had experienced severe atypical NTT as a conse-
quence of earlier RT were identified from follow-up clinics,
forming one group; ten patients who had experienced little or
no NTT acted as one control group; seven healthy, noncancer
individuals comprised a second control group. Patient details
including tumour histology and stage, radiotherapy dose and
level of NTT experienced measured on the relevant RTOG
scale are shown in Table 1. None of the patients selected for
the study had received prior chemotherapy.
All blood samples were obtained by the clinical team with
full patient informed consent. The testing process was per-
formed by the laboratory team who were blinded to the iden-
tity of the patients. Limitations of ethical approval dictated
that only one blood sample be taken from each patient; how-
ever, the number of PBL produced allowed testing of each
sample on at least two separate occasions.
Isolation of PBL
A 10-ml venous draw was taken from the patient’s arm into
heparinised containers, which were transported within 1 hr
to Brunel University (Institute of Cancer Genetics and Phar-
macogenomics). PBL were isolated by density centrifugation
over Ficoll-Hypaque lymphocyte separation medium (LSM)
(Fisher Scientific, Leicestershire, UK) according to the stand-
ard methods. In brief, 10 ml of blood was diluted 1:1 with
RPMI 1640 medium (Fisher Scientific) and was carefully laid
on to an equal volume of LSM and subjected to 20-min cen-
trifugation at 400g in a table top centrifuge (Heraeus GmbH,
Hanau, Germany). The buffy coat containing the PBL was
carefully removed from the interface of the LSM and the
blood serum and washed by a further centrifugation in 20-ml
serum-free RPMI 1640 medium at 450g in a table top centri-
fuge. The number of PBL in each sample was determined
with a haemocytometer; 107 cells were frozen in liquid nitro-
gen for future use, and 4  106 cells were set up in a T75
cell culture flask (Nunc, Fisher Scientific) in RPMI 1640
medium containing 10% foetal calf serum, 2 mM L-glutamine
and 100 U/ml penicillin and streptomycin (Fisher Scientific).
Cells were incubated in a humidified atmosphere at 37C
with 5% CO2 in air before gamma irradiation and staining
for cellular c-H2AX expression.
Irradiation of PBL
PBL were irradiated in batches of four to five samples,
according to the attendance of patients at clinic. Following
the removal of 106 PBL (untreated control), the remaining
cells were irradiated to a dose of 2-Gy using gamma radiation
from a 60Cobalt source (Puridec Technologies, Oxfordshire,
UK) sited at a distance of 25 cm with a dose rate between
1.3 and 1.4 Gy per minute. A total of 106 cells were harvested
from the flask after 30 min, 5 hr and 24 hr for flow cytomet-
ric analysis of c-H2AX induction.
DNA damage dose–response curve
To determine the level of fluorescence induced by different
doses of gamma radiation, and thus the level of c-H2AX
induction and DNA damage, PBL from a normal noncancer
individual were irradiated with 0-, 2-, 4-, 6- and 8-Gy gamma
irradiation and subjected to flow cytometric analysis. Cells
were fixed and stained as described below.
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Immunocytochemical detection of c-H2AX in PBL
In brief, untreated control cells and those treated with 2-Gy
gamma radiation were pelleted by centrifugation and washed
twice in phosphate-buffered saline (PBS) (Sigma Chemicals,
Dorset, UK) before fixing in methanol/acetone (50:50% v/v) for
5 min at 4C. Following three washes in PBS, mouse monoclo-
nal anti-c-H2AX (Millipore UK, Hampshire, UK) at 1:10,000
dilution was added to the cells for 1 hr at room temperature,
followed by washing in PBS. Two hundred microliters of Alexa
FluorVR 488 goat anti-mouse IgG (Invitrogen UK, Paisley, UK)
diluted 1:1,000 was then applied to each sample for 1 hr at
room temperature in the dark followed by counterstaining with
1 lg/ml propidium iodide. Cells were stored for not more
than 24 hr before the commencement of flow cytometry. The
level of fluorescence in control and irradiated cells was esti-
mated by counting a minimum of 20,000 cells at each time
point using an Epics XL-MCL flow cytometer (Beckman-
Coulter, Berkshire, UK). The fluorescence in cells postirradia-
tion was compared to the level of fluorescence in untreated
control cells to provide a measure of relative fluorescence.
Table 1. Clinical details for all cancer patients (NOR and OR) used in this study
Patient Sex
Age at
treatment Histology Stage
Dose
(Gy) Fractions
Normal tissue toxicity
A 5 acute, C 5 chronic
RTOG
scale
OR1 F 57 Colon adenocarcinoma IV 44 22 C: Gastrointestinal stenosis/fibrosis 4
OR2 F 52 Breast adenocarcinoma II 50 25 C: Brachial plexopathy 4
OR3 F 47 Breast adenocarcinoma I 50 25 C: Brachial plexopathy,
chest wall ulceration
4
OR4 F 41 Breast adenocarcinoma II 50 25 C: Brachial plexopathy 4
OR5 F 23 Brain arteriovenous malformation N/A 17.51,2 1 C: Radionecrosis 4
OR6 F 45 Breast tubular carcinoma IIA 50 25 A: Brisk skin changes 3
C: Severe telangiectasia
OR7 F 45 Breast inv ductal carcinoma IA 40.05 15 A: Severe skin changes 3
þ11.13 þ5 C: Severe skin fibrosis
OR8 M 56 Larynx SCC I 55 20 A: Severe skin changes 3
OR9 F 41 Thyroid medullary carcinoma III 50 25 A: Severe skin changes 3
C: Late fibrosis
OR10 F 60 Thyroid papillary carcinoma IVa 50 25 A: Severe skin changes 3
C: Late fibrosis
OR11 F 56 Breast IIB 50 25 A: Severe skin changes 3
C: Severe telangiectasia
OR12 F 46 Breast adenocarcinoma II 13.354 5 A: Brisk skin reaction 3
C: Brachial plexopathy
NOR1 M 39 Pituitary adenoma N/A 45 25 None 0
NOR2 M 49 Thyrotoxic eye disease N/A 20 12 None 0
NOR3 M 35 Brain glioblastoma II (WHO) 54 30 A: Fatigue 1
NOR4 M 54 SCC metastatic to parotid IV 60 30 A: Skin 1
NOR5 M 66 Prostate adenocarcinoma III 64 32 A: Urinary frequency 1
NOR6 M 64 Prostate adenocarcinoma III 64 32 A: Urinary frequency, loose stool 1
NOR7 F 56 Breast II 40.05 15 A: Skin 1
NOR8 F 61 Breast I 40.05 15 A: Skin 1
NOR9 F 65 Cervix SCC IIIB (FIGO) 50.4 28 A: Urinary frequency,
dysuria, stool frequency
1
þ145 þ2
NOR10 M 68 Prostate adenocarcinoma IIB 70 35 A: Urinary urgency 1
Staging system uses AJCC system unless otherwise stated.
1Stereotactic radiotherapy. 2Although a high single dose, this is typical of radiosurgical practice and this prescription did not lead to similar
sequelae in more than 200 other patients. 3Boost to tumour bed. 4Treatment was stopped after five treatments to prevent further toxicity (intended
dose 40.05 Gy in 15 fractions). 5Brachytherapy.
Abbreviations: SCC: squamous cell carcinoma; WHO: World Health Organisation; FIGO: International Federation of Gynecology and Obstetrics.
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Statistical analysis
Differences in the relative fluorescence in the PBL between
patient groups were compared using a Student’s unpaired
t-test, specifically, c-H2AX retention in PBL after 24 hr.
Results
Induction of fluorescence with escalating gamma radiation
dose
This experiment was essential to determine the dynamic
range of fluorescence induction with ionising radiation and
to determine an appropriate dose of radiation to use for
future analyses with patient samples. Following the exposure
of PBL from a normal individual to a range of gamma radia-
tion doses, an 1.5- to 2-fold increment of relative fluores-
cence was observed with each dose (Fig. 1). The result of this
dose–response experiment confirmed that future experiments
would be conducted by exposing the samples to 2-Gy gamma
radiation, an appropriate dose because most radical radio-
therapy protocols are administered in a fractionated regimen
of 2-Gy per dose.
Determination of c-H2AX induction in patient PBL
Twenty-nine blood samples were analysed in the flow cyto-
metric assay: 12 from OR patients who had experienced severe
atypical NTT after radiotherapy, ten from ‘‘non-overreactor’’
(NOR) patients who had experienced little or no NTT and
seven from normal noncancer individuals (N) who had not
received prior irradiation.
Across all groups there is a dramatic induction of fluores-
cence in PBL samples stained with c-H2AX antibodies
following 2-Gy gamma radiation exposure, representing the
induction of DNA DSB. There is then a rapid reduction of
fluorescence in PBL samples from healthy noncancer individ-
uals, such that within 5 hr of irradiation levels have fallen to
preirradiated control levels as DNA DSB are repaired and the
c-H2AX histone proteins are dephosphorylated (Fig. 2). A
similar pattern of damage and timely repair is seen for the
NOR group (Fig. 3). However, in those samples taken from
OR patients, there is a striking difference with maintenance
of the level of fluorescence over a 24 hr period indicating
persistent c-H2AX expression and reduced DNA DSB repair
(Fig. 4). For reference, a sample of PBL from a patient with
the inherited DNA DSB repair disorder A-T is included,
demonstrating very similar results to the OR patients.
Figure 1. The induction of fluorescence in PBL derived from a
normal (noncancer) individual. The level of fluorescence (c-H2AX
induction) increases with dose of gamma radiation by 1.5- to 2-
fold per 2 Gy of gamma radiation. Error bars represent standard
error of the mean fluorescence levels derived from at least two
independent experiments. For all further experiments using patient
samples, a dose of 2-Gy gamma radiation was used.
Figure 2. The results derived from the flow cytometric analysis of
c-H2AX induction from seven normal noncancer patients (normal:
N1–7). A rapid rise in radiation-induced DNA DSB is revealed by
an increase in relative fluorescence 30 min postexposure. This is
followed by a steady decline in fluorescence, due to repair of DNA
DSB and at 24 hr fluorescence levels have returned to near
unirradiated levels. The data are derived from at least two
experiments for each patient sample, and the standard error of the
mean (not shown) is less than 10%.
Figure 3. The results derived from the flow cytometric analysis of c-
H2AX induction from ten patients who did not experience excessive
NTT (non-overreactor: NOR1–10). A rapid rise in radiation-induced
DNA DSB is revealed by an increase in relative fluorescence 30 min
postexposure. This is followed by a steady decline in fluorescence,
due to repair of DNA DSB and at 24 hr fluorescence levels have
returned to near unirradiated levels. The data are derived from at
least two experiments for each patient sample, and the standard
error of the mean (not shown) is less than 10%.
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Figure 5 shows the mean level of induced fluorescence for
each group with standard error plotted. Of note, the fluores-
cence induced at 30 min differs between groups: NOR
patients routinely had a higher level of c-H2AX-associated
fluorescence than either OR patients or normal individuals.
The level of fluorescence at 24 hr was compared across
groups using Student’s unpaired t-tests: there was signifi-
cantly higher retention of fluorescence in the OR compared
to the NOR group (p < 0.0001) and with the N group (p <
0.0001). There was no significant difference between the
NOR group and the N group (p ¼ 0.6).
Discussion
In our report, we present the results of a study examining
whether patients who have suffered excessive toxicity from
radiotherapy have impaired normal cell DNA repair mecha-
nisms, with the ultimate aim of developing a diagnostic test
to predict such abnormal response. We used flow cytometric
analysis of c-H2AX induction and removal to measure DNA
DSB damage and repair in the PBL of cancer patients who
had experienced excessive acute and/or late NTT after radio-
therapy. These were compared with patients who experienced
little or no acute NTT and had developed no significant late
NTT within at least 1 year of radiotherapy and with normal
noncancer individuals. The c-H2AX assay was selected for
this analysis as it has been shown to be a reliable measure of
DNA DSB repair and it is a relatively rapid test from which
results can be provided quickly for clinical purposes.18,19
We have demonstrated that there is a significant relation-
ship between the persistence of c-H2AX expression caused
by ionising radiation and the level of NTT experienced: at
24 hr there was markedly higher retention of c-H2AX in PBL
from OR patients than NOR or unirradiated normal non-
cancer control individuals. This finding is of importance for
both experimental and clinical oncology as it provides evi-
dence that the c-H2AX assay when used in a flow cytometric
setting may be able to ‘‘predict’’ NTT in cancer patients.
Although our results are not strictly predictive as most testing
was performed after radiotherapy was delivered, it is certainly
plausible that a prospective study could demonstrate that
those patients with abnormal persistence of c-H2AX expres-
sion subsequently developed greater than expected toxicity.
Although our assay was able to reliably differentiate
between patients clinically classified as NOR or OR patients,
we could not differentiate between those individuals with the
severest NTT (RTOG 4) and those with moderately severe
NTT (RTOG 3). This lack of apparent sensitivity should not,
however, be seen as a failing of the test as there are a great
many factors involved in the development of toxicity, not
least the variation between different clinical observers in scor-
ing toxicity grade. Other factors include and are not limited
to total dose, dose per fraction, duration of treatment, nature
of normal tissue irradiated, whether acute or late toxicity is
assessed (owing to different a/b ratios) and exposure to
chemotherapy, either neoadjuvant or concomitant or other
pharmaceutical modifiers. A further study with a larger
patient cohort attempting to control for such factors may
provide useful results, especially if coupled with more refined
and sensitive flow cytometry such as the Imagestream (Cro-
nus, Surrey, UK) in which DNA DSB can be quantified at
the individual cell level.
However, a predictive test would be of most clinical bene-
fit in being able to detect those (relatively rare) individuals at
risk of severe toxicity far greater than would be expected for
a proposed treatment plan; for example, individuals who may
suffer severe long-term consequences of treatment—as in the
carefully selected OR group here—or even fatal complications
as have been noted above. If the predictive test indicated that
radiotherapy had a very high probability of causing severe
NTT, an alternative strategy could be entertained, such as
surgery for primary treatment, or omission of radiotherapy
in the adjuvant setting. If radiotherapy was not contraindi-
cated but still thought likely to cause notable toxicity, the op-
portunity would arise to tailor treatment to the patient, such
as by offering intensity-modulated radiotherapy to minimise
the regions of higher dose to uninvolved organs at risk. Our
results strongly suggest that the c-H2AX assay has merit as a
predictor of excessive toxicity. Although it may not be feasi-
ble to offer the test to every patient embarking upon a course
of radical radiotherapy, a targeted approach to patients
thought to have a risk of impaired DNA repair, such as those
Figure 4. The results derived from the flow cytometric analysis of c-
H2AX induction from 12 cancer patients who experienced severe
NTT (overreactor: OR1–12). Patients classified as RTOG4 responders
are depicted by an unbroken line (------------------------------------) and those
classified as RTOG3 are identified by broken lines (––––––––––). A
rapid rise in radiation-induced DNA DSB is revealed by an increase
in relative fluorescence 30 min postexposure. Compared to Figure
2, there is retention of fluorescence in the irradiated PBL derived
from this group of patients. This retention of fluorescence is
consistent with a failure to repair DNA DSB. This is similar to the
profile of repair observed in a PBL sample derived from a patient
with ataxia telangiectasia (A-T) with a well-established defect in DNA
DSB repair (–– - –– - –– - ––). The data are derived from at least two
experiments for each patient sample, and the standard error of the
mean (not shown) is less than 10%.
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with a strong family history of malignancy, known repair
defect such as BRCA1 or BRCA2 or even excessive clinical
reaction to neoadjuvant chemotherapy, would be a practical
alternative. It has been demonstrated that BRCA1 patients
are hypersensitive to DNA-damaging cytotoxic chemother-
apy,20 and there may also be scope for using the c-H2AX
assay to predict response to chemotherapy.
Interestingly, we observed that there are significantly
different levels of fluorescence induced at 30 min after 2-Gy
gamma exposure between the groups of individuals. The
highest levels of fluorescence were observed in the ten NOR
patients, and the lowest levels of damage induction were par-
adoxically observed in PBL derived from OR patients, even
though these cells failed to effectively repair the DNA DSB as
measured in this assay. The reasons for these observations
remain unclear. One explanation may be the reported obser-
vation of significant interindividual differences in the induc-
tion of c-H2AX when measured with flow cytometry.21,22
However, it is difficult to accept this as the sole explanation
because the difference between groups is so marked: where
this to be the only cause one would expect more of an over-
lap between groups owing to an averaging of differences
between individuals across groups. The question is raised as
to whether OR patients are not only less able to repair DNA
damage in response to irradiation but perhaps less able to
detect such damage, demonstrated by the relatively lower
induction of c-H2AX. Further research would provide valua-
ble insight into this postulation.
Although we have found a strong correlation between
c-H2AX persistence and the development of excessive acute
or late NTT, other studies have not demonstrated such a
strong relationship. Werbrouck et al. observed no differences
in kinetics of c-H2AX foci following irradiation of PBL from
29 patients with gynaecological malignancies who developed
differing levels of NTT.23 Vasireddy et al. examined c-H2AX
induction in 18 patients with acute and late NTT classified as
RTOG 3 and saw similar levels of c-H2AX induction and
removal over a 24 hr period for the majority of patients and
controls.24 However, these authors were in fact able to detect
a patient with defective DNA repair mechanisms and suggest
that determining c-H2AX levels in irradiated PBL may con-
tribute to identifying individual radiosensitivity. The discord-
ance between these observations and ours may well reflect
the fact that individuals with DNA repair defects are rare in
the general, or even cancer patient, population. Any prospec-
tive study is unlikely to encounter many such patients unless
including very large numbers; our study targeted ORs identi-
fied on clinical grounds and compared them with known
normal reactors, thus greatly increasing the likelihood of
detecting a true difference.
In summary, our study has demonstrated cancer patients
developing severe NTT fail to repair radiation-induced DNA
DSB as efficiently as either patients experiencing little or no
NTT and normal noncancer individuals although it does not
probe the mechanism of this inefficiency. It is an interesting
question to speculate whether the OR patients described here
may harbour subtle hypomorphic mutations in key DNA
repair genes involved in the recognition and processing of
DNA DSB. Previous studies have demonstrated that individu-
als with mutations in DNA DSB repair genes exhibit extreme
clinical and cellular hypersensitivity to radiation, and further
study of our patient cohort may yet reveal such mutations.
From a clinical standpoint, our study provides the exciting
prospect that a clinician may be able to predict and so avoid
the overresponse of patients to radiotherapy before a single
dose has been delivered.
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